Investor venBio Global Strategic Fund II L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by venBio Global Strategic Fund II L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2022-09-15 13D/A AKRO / Akero Therapeutics, Inc. 2,315,893 714,000
2022-06-07 13G/A CMPI / Checkmate Pharmaceuticals Inc 3,673,374 0
2022-02-14 13G/A HRMY / Harmony Biosciences Holdings, Inc. 3,504,624 2,740,411
2021-05-07 13D/A AKRO / Akero Therapeutics, Inc. 2,668,717 2,315,893
2021-05-07 13G IMPL / Impel Pharmaceuticals Inc. 2,759,791
2021-02-16 13G HRMY / Harmony Biosciences Holdings, Inc. 3,504,624
2020-10-06 13G CMPI / Checkmate Pharmaceuticals Inc 3,673,374
2020-10-01 13D ALXO / ALX Oncology Holdings Inc. 9,799,331
2020-09-09 13D/A AKRO / Akero Therapeutics, Inc. 3,322,138 2,668,717
2020-04-16 13D/A VYNE / VYNE Therapeutics Inc. 1,461,552 0
2020-01-15 13D/A AKRO / Akero Therapeutics, Inc. 3,954,858 3,322,138
2019-06-26 13D AKRO / Akero Therapeutics, Inc. 3,954,858
2019-02-14 13G/A NBRV / Nabriva Therapeutics Plc 2,122,962 0
2019-02-14 13G/A APLS / Apellis Pharmaceuticals, Inc. 3,579,305 1,790,102
2018-02-09 13G/A NBRV / Nabriva Therapeutics Plc 222,296 2,122,962
2018-02-09 13G APLS / Apellis Pharmaceuticals, Inc. 3,579,305
2018-02-08 13D VYNE / VYNE Therapeutics Inc. 1,461,552
2017-05-08 13G VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) 7,000,000
2017-05-08 13G VNAPF / Verona Pharma Plc 7,000,000
2017-02-13 13G/A NBRV / Nabriva Therapeutics Plc 117,787 222,296
2016-04-29 13G NBRV / Nabriva Therapeutics Plc 117,787